RNAC compared with SMTI: revenue, margins and what each company keeps, and the suppliers and customers both name

RNACCartesian Therapeutics, Inc.

Mkt capRevenueRevenue

SMTISanara MedTech Inc.

Mkt capRevenueRevenue

Compare

RNACCartesian Therapeutics, Inc.

SMTISanara MedTech Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

RNAC: latest quarter is a loss; flow not drawable. SMTI: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only RNAC 8

BIIBBiogen MA, Inc., or Biogensupplier

—National Institutes of Healthunlistedsupplier

—Genovis AB (publ.)unlistedsupplier

—NCIunlistedsupplier

4 more · RNAC chain ›

Shared 0

No disclosed counterparties: SMTI.

Only SMTI 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

RNAC, solidSMTI, dashed

RNACCartesian Therapeutics, Inc.

6.42· pre 6.42· delayed

Mkt cap$191.8MRevenue$78,000Q1 FY26Revenue$3MFY25

SMTISanara MedTech Inc.

32.12· pre 32.12· delayed

Pre-marketNov 3 '26delayed

Mkt cap$295.6MRevenue$28MQ2 FY26Revenue$103MFY25

Compare

Pre-marketNov 3 '26delayed

RNACCartesian Therapeutics, Inc.

SMTISanara MedTech Inc.

6.42pre 6.42delayed

Price

32.12pre 32.12delayed

$191.8M

Mkt cap

$295.6M

Q1 FY26$78,000

Revenue

$28MQ2 FY26

FY25$3M

Revenue

$103MFY25

RNAC6.42vsSMTI32.12Pre-marketNov 3 '26delayed